Loading...
Market
Will GRO Biosciences initiate a clinical trial for NSAA-based therapy by end of 2024?
2
GRO Biosciences•Atlas Venture•Access Biotechnology•Leaps by Bayer•Redmile Group•Digitalis Ventures•iEndeavors•Pillar•Dan
Resolution / Starting Odds
Yes • 50%
No • 50%
Clinical trial databases, press releases from GRO Biosciences
Story
GRO Biosciences Secures $60.3M Series B Financing Co-Led by Atlas Venture and Access Biotechnology
Jul 19, 2024, 12:05 PM
GRO Biosciences has successfully closed a $60.3 million Series B financing round, co-led by Atlas Venture and Access Biotechnology. The funds will be used to advance its pipeline, which focuses on incorporating non-standard amino acid (NSAA) chemistries into therapies. This round also saw participation from previous investors, including Leaps by Bayer, Redmile Group, Digitalis Ventures, and iEndeavors. The financing marks a significant milestone for the company, which has been backed by Pillar since its pre-seed stage. Dan and his team have been pivotal in developing the GRO platform and product pipeline.
View original story
Similar markets
Yes • 50%
No • 50%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
